Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease

被引:24
作者
VanGool, SW
Delabie, J
Vandenberghe, P
Correvits, L
DeWolfPeeters, C
Ceuppens, JL
机构
[1] CATHOLIC UNIV LEUVEN,FAC MED,EXPT IMMUNOL LAB,B-3000 LOUVAIN,BELGIUM
[2] CATHOLIC UNIV LEUVEN,DEPT PATHOPHYSIOL,LAB EXPT HEMATOL,B-3000 LOUVAIN,BELGIUM
[3] CATHOLIC UNIV LEUVEN,DEPT PEDIAT,B-3000 LOUVAIN,BELGIUM
[4] CATHOLIC UNIV LEUVEN,DEPT PATHOL 2,B-3000 LOUVAIN,BELGIUM
关键词
Hodgkin's disease; non-Hodgkin's lymphomas; CD80; CD86; tumor immunology;
D O I
10.1038/sj.leu.2400683
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Ligation of CD28 on T cells with its natural ligands B7-1 (CD80) or B7-2 (CD86) provides a major costimulatory signal for T cells and is of potential importance for tumor rejection. We previously reported a strong expression of B7-1 on Reed-Sternberg cells and anaplastic large cell lymphoma cells. We report here our findings on B7-2 expression by malignant lymphomas (n = 70). B7-2 was present on the neoplastic cells of anaplastic large cell lymphoma in two of three cases studied, and on a subpopulation of the malignant cells in one out. of four cases of follicular lymphoma. B7-2 was not expressed by the neoplastic cells of the other non-Hodgkin's lymphomas (n = 32), including T cell-rich B cell lymphoma. In contrast, Reed-Sternberg cells in lymph nodes affected by Hodgkin's disease ape strongly positive for B7-2 (n = 31). Evidence for a functional correlate of this expression was obtained by our findings that the combination of anti-B7-1 and anti-B7-2 monoclonal antibodies was more effective than each separately in blacking allogeneic T cell activation (proliferation and cytokine secretion) by Hodgkin's disease-derived cell lines as stimulators. The possible role of B7-1 and B7-2 expression for the course and symptomatology of Hodgkin's disease is discussed.
引用
收藏
页码:846 / 851
页数:6
相关论文
共 28 条
[1]
Baskar S, 1996, J IMMUNOL, V156, P3821
[2]
CONSTITUTIVE EXPRESSION OF B7 RESTORES IMMUNOGENICITY OF TUMOR-CELLS EXPRESSING TRUNCATED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULES [J].
BASKAR, S ;
OSTRANDROSENBERG, S ;
NABAVI, N ;
NADLER, LM ;
FREEMAN, GJ ;
GLIMCHER, LH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5687-5690
[3]
MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II(+)B7-1(+) TUMOR-CELLS ARE POTENT VACCINES FOR STIMULATING TUMOR REJECTION IN TUMOR-BEARING MICE [J].
BASKAR, S ;
GLIMCHER, L ;
NABAVI, N ;
JONES, RT ;
OSTRANDROSENBERG, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) :619-629
[4]
TUMOR IMMUNOGENICITY DETERMINES THE EFFECT OF B7 COSTIMULATION ON T-CELL-MEDIATED TUMOR-IMMUNITY [J].
CHEN, LP ;
MCGOWAN, P ;
ASHE, S ;
JOHNSTON, J ;
LI, YW ;
HELLSTROM, I ;
HELLSTROM, KE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :523-532
[5]
COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4 [J].
CHEN, LP ;
ASHE, S ;
BRADY, WA ;
HELLSTROM, I ;
HELLSTROM, KE ;
LEDBETTER, JA ;
MCGOWAN, P ;
LINSLEY, PS .
CELL, 1992, 71 (07) :1093-1102
[6]
GENERATION OF MONOCLONAL-ANTIBODIES TO HUMAN LYMPHOCYTE CELL-SURFACE ANTIGENS USING INSECT CELLS EXPRESSING RECOMBINANT PROTEINS [J].
DEBOER, M ;
CONROY, L ;
MIN, HY ;
KWEKKEBOOM, J .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 152 (01) :15-23
[7]
HISTIOCYTE-RICH B-CELL LYMPHOMA - A DISTINCT CLINICOPATHOLOGICAL ENTITY POSSIBLY RELATED TO LYMPHOCYTE PREDOMINANT HODGKINS-DISEASE, PARAGRANULOMA SUBTYPE [J].
DELABIE, J ;
VANDENBERGHE, E ;
KENNES, C ;
VERHOEF, G ;
FOSCHINI, MP ;
STUL, M ;
CASSIMAN, JJ ;
DEWOLFPEETERS, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (01) :37-48
[8]
DELABIE J, 1993, BLOOD, V82, P2845
[9]
DIEHL V, 1982, CANCER TREAT REP, V66, P615
[10]
Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML [J].
DunussiJoannopoulos, K ;
Weinstein, HJ ;
Nickerson, PW ;
Strom, TB ;
Burakoff, SJ ;
Croop, JM ;
Arceci, RJ .
BLOOD, 1996, 87 (07) :2938-2946